Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.68 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15394735 | 0.95 | RXFP1 (0.66) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL3792597 | 0.91 | TRPA1 (0.68) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL12584442 | 0.89 | TRPA1 (0.75) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL3793531 | 0.89 | TRPA1 (0.57) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL15394741 | 0.89 | TRPA1 (0.68) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL3789024 | 0.88 | RXFP1 (0.69) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL17527089 | 0.88 | RXFP1 (0.69) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL1064145 | 0.88 | TRPA1 (0.72) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL15394615 | 0.86 | RXFP1 (0.69) | TRPA1RXFP1TP53PORCNTHRB | |
| SCHEMBL10130857 | 0.86 | TRPA1 (0.77) | TRPA1RXFP1TP53PORCNTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170151248-A1 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS | ELI LILLY AND COMPANY | 2017-06-01 | — | — | US | disclosed |
| US-9260430-B2 | Use of TRPA1 antagonists to prevent or treat infections caused by biological-warfare agents | HYDRA BIOSCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| WO-2010138879-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1 | HYDRA BIOSCIENCES, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138879-A1 | COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO TRPA1 | HYDRA BIOSCIENCES, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151248-A1 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885RXFP1 396/4885TP53 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.